Venus Remedies Secures Saudi FDA Approval for Plerixafor Oncology Therapy
Venus Remedies receives Saudi FDA approval for Plerixafor, marking its first global marketing authorisation for the specialty oncology therapy used in stem cell mobilisation for multiple myeloma and non-Hodgkin lymphoma patients undergoing autologous transplantation.
Saudi FDA Pharmaceutical Approval | 25/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy